Pere Fusté

No ORCID on file · 4 papers in corpus
2024
O-RADS MRI scoring system: key points for correct application in inexperienced hands.
Insights into imaging ·doi:10.1186/s13244-024-01670-3

ObjectivesTo evaluate the efficacy of the O-RADS MRI criteria in the stratification of risk of malignancy of solid or sonographically indeterminate ovarian masses and assess the interobserver agreement of this classification between experie…

other 2023
Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement
Gynecologic oncology ·doi:10.1016/j.ygyno.2023.11.007

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial …

2022
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.
Diagnostics (Basel, Switzerland) ·doi:10.3390/diagnostics12010226

(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively identify epithelial ovarian cancer (EOC) or metastatic cancer in the ovary (MCO). (2) METHODS: single center retrospective study, including…

article 2021
HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected
The Journal of international medical research ·doi:10.1177/03000605211047701

OBJECTIVE: To analyze the utility of carbohydrate antigen (CA)125 and human epididymis protein 4 (HE4) to detect malignancy in women with ovarian endometriosis, when ovarian cancer is suspected and ultrasonography results are inconclusive. …